**Cardiovascular, Renal and Metabolism (CVRM)**

Our mission is to save patients’ lives by jointly addressing their cardio-renal-metabolic risks.

### The growing unmet need in CVRM

Despite scientific advancements, cardiovascular disease (CVD) can cause high residual risk for recurrent cardiac events in certain patients and remains the #1 cause of death globally.\(^1,2\)

From 2011 to 2025, the cumulative economic losses in low-income and middle-income countries from CVD are projected to be, close to US $3.76 trillion.\(^3\)

More than 424.9 million adults worldwide have diabetes, with up to 628.6 million expected by 2045.\(^4\)

An estimated 17.5 million people worldwide die from CVD in a year.\(^1\)

An estimated 200 million people worldwide have CKD.\(^2\)

### Overlapping disease states

Science is uncovering commonalities between CV, renal and metabolic disease, explaining why the idea of reducing CV risk is so complex.

With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.

CVD is the leading cause of death in people with CKD and people with diabetes.\(^5,6\)

Type-2 diabetes is one of the top causes of CKD.\(^5\)

Hyperkalaemia occurs in up to 50% of patients with CKD and approximately 20% of patients with chronic heart failure (HF) taking mineralocorticoid receptor antagonists.\(^7,8\)

### Our distinctive approach to CVRM

We continue to strengthen our commitment to following the science through:

**Strategic Partnerships**

**Rigorous Clinical Studies**

We are evaluating the use of our medicines in large patient populations in both established and emerging markets. These trials include ambitious global randomised clinical trials that are as close as possible to clinical practice, as well as transformational real-world evidence research.

60,000+ patients participating in Research & Development-led CV trials at 6,000+ sites worldwide

25+ therapies and therapy combinations in our early to late-stage pipeline

We are committed to delivering life-changing results for people living with CVRM, with medicines that have the potential to offer improved outcomes to hundreds of millions of patients across the globe.

---

**Reference**